Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05081063 · ClinicalTrials.gov registry record · Phase 3

Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients

A Phase 3 study, sponsored by Loma Linda University.

Completed
Registry status
Phase 3
Development phase
199
Enrollment target

NCT05081063 is a Phase 3 study that has completed, run by Loma Linda University. The registered enrollment target is 199 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05081063, a Phase 3 study, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
Phase 3
Development phase
199 participants
Enrollment target

Study Summary

Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion. Objectives 1. Evaluate PRBC equivalents transfused in each group in the first 24 hours (Primary outcome) 2. Evaluate total transfusion in each group in the first 24 hours (Secondary Outcome) including breakdown by FFP equivalents, platelet units, and cryoprecipitate 3. Evaluate 6 hour, 24 hour, and hospital mortality (Secondary Outcome) 4. Evaluate ICU outcomes in each group

Interventions

  • COMBINATION_PRODUCT Routine labs

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2022-03-05
Est. Completion 2023-05-15
Phase Phase 3

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT05081063

The ClinicalTrials.gov registry entry for NCT05081063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Routine labs is the first listed.

NCT05081063 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05081063 about?

NCT05081063 is a clinical study titled "Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients". Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion. Objectives 1. Evaluate PRBC equivalents transfused in each group in the first 24 hours (Primary outcome) 2. Evaluate total transfusion in each group in the first 24 ...

What is the current status of trial NCT05081063?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 199 participants. The study started on 2022-03-05. Estimated completion is 2023-05-15.

What interventions are being tested in trial NCT05081063?

The interventions under investigation include: Routine labs (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05081063?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.